Loading clinical trials...
Loading clinical trials...
Prospective Trial to Assess Real-world Outcomes and Predictive Biomarkers of Response to Pembrolizumab With or Without Chemotherapy in Black Patients With NSCLC
Conditions
Interventions
Cisplatin
Carboplatin
+4 more
Locations
5
United States
Moffitt Cancer Center
Tampa, Florida, United States
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, United States
TidalHealth Peninsula Regional
Salisbury, Maryland, United States
Montefiore Medical Cancer Center
The Bronx, New York, United States
Baptist Clinical Research Institute
Memphis, Tennessee, United States
Start Date
June 13, 2025
Primary Completion Date
January 1, 2030
Completion Date
January 1, 2030
Last Updated
April 2, 2026
NCT07431827
NCT06427941
NCT07164313
NCT06253871
NCT07361497
NCT07510724
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions